Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2014

View Archived Issues

In cellulo synthesis of potent oligomeric inhibitors of disease-causing RNAs

Recent FDA orphan drug designations for cancer treatments

OncoEthix to begin phase Ib trial of OTX-015

Lucitanib study in squamous non-small cell lung cancer enrolls first patient

Cellceutix reports positive data from phase IIb trial of brilacidin in ABSSSI

Biothera announces phase Ib trial of mucin-1-targeted antibody BTH-1704 and Imprime PGG

Bristol-Myers Squibb reports pipeline progress of third quarter 2014

GSK seeks approval of additional indications for lamotrigine in Japan

RPL-554 in combination with MRP4 blocker as potential adjunct therapy for CF

Researchers present new genetic animal models of disease

CSL Limited to acquire Novartis influenza vaccines business

Aileron Therapeutics begins phase I/II study of ALRN-6924

CHMP recommends approval of Duavive

Preclinical efficacy of a selective HSP90alpha/beta-inhibitor against MM

Octagam 10% now available in the U.S. for chronic ITP

Orion Corp. discloses new FGF-1 inhibitors

Temple University divulges new 5-HT7 receptor antagonists

Bristol-Myers Squibb patents new HIV integrase inhibitors

Takeda Pharmaceutical discloses novel CH24H inhibitors

Bristol-Myers Squibb presents results of the phase III HALLMARK-QUAD trial

Novel compounds for tuberculosis disclosed by Charles University

EMA committee recommends approval for Rixubis in patients with hemophilia B

Pembrolizumab given FDA Breakthrough Therapy Designation for NSCLC

Cocrystal Pharma develops Ebola high-throughput screening technology

Akebia releases topline results from phase IIb study of AKB-6548 in patients with CKD and anemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...